'Cool' drug, 'unconvincing' data: FDA panel rejects MDCO's cangrelor
This article was originally published in Scrip
While it was praised for its novel P2Y12 platelet inhibitor, The Medicines Company (MDCO) failed to persuade a federal panel of advisers on 12 February to recommend approval of cangrelor to reduce thrombotic cardiovascular events, including stent thrombosis, in patients with coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI), or cardiac stent procedures.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.